Quilipta manufactured by Abbvie goes by the name Aquipta in the UK.
Information about Qulipta (Atogepant)
Qulipta (atogepant) is a prescription medication used to prevent and manage episodic migraines. It is an oral medication that belongs to a class of drugs called CGRP (calcitonin gene-related peptide) receptor antagonists. These medications work by blocking the CGRP receptors involved in the migraine process, which helps reduce the frequency of migraines and their associated symptoms. Qulipta is specifically designed for the prevention of migraines in adults who experience episodic migraines, defined as having 4 to 14 migraine days per month.
Primary Indications for Qulipta (Atogepant)
- Qulipta is primarily used to prevent episodic migraines in adults. It does not treat acute migraine attacks but helps reduce the number of migraine days over time.
- It is a long-term treatment aimed at reducing the frequency and severity of migraines in individuals with a history of recurrent migraine attacks.
Key Ingredient
Key Benefits
- The primary benefit of Qulipta is its ability to reduce the frequency of migraine attacks. Studies have shown that it can significantly decrease the number of migraine days per month.
- Qulipta is taken orally, typically once daily, which is more convenient for long-term use compared to other migraine treatments, such as injectable medications.
- Clinical trials have shown that atogepant is generally well-tolerated, with fewer side effects compared to some other migraine prevention medications.
- By reducing the number of migraines, Qulipta can help improve a person's overall quality of life, allowing for fewer disruptions due to migraines.
Direction of Use
- The typical starting dose of Qulipta is 60 mg once a day. Depending on the patient's response and tolerance, the dose may be adjusted by the healthcare provider. The medication is available in tablet form.
- Take Qulipta exactly as prescribed by your healthcare provider, usually once a day, with or without food. It's essential to take it consistently to achieve the best results.
- If you miss a dose, take it as soon as you remember, unless it's almost time for your next dose. Do not double the dose to make up for a missed dose.
Safety Concerns
- Atogepant is metabolized in the liver, so individuals with liver impairment may need dose adjustments. Regular liver function tests may be recommended by your healthcare provider.
- Some common side effects of Qulipta include nausea, constipation, and fatigue. Most side effects are mild and may resolve over time.
- Atogepant may interact with other medications, including certain liver enzyme inhibitors. It's essential to inform your healthcare provider of any other medications you are taking, including over-the-counter drugs and supplements.
- The safety of Qulipta during pregnancy or breastfeeding has not been established. If you are pregnant, planning to become pregnant, or breastfeeding, discuss the potential risks and benefits with your healthcare provider.
- Qulipta is intended for migraine prevention, not for the treatment of an active migraine attack. If you experience a migraine while on Qulipta, use an appropriate acute treatment as prescribed by your healthcare provider.
Avoid Qulipta (Atogepant) If
- Avoid using Qulipta if you are allergic to atogepant or any of the other ingredients in the medication.
- If you have severe liver impairment (such as cirrhosis), Qulipta may not be suitable for you. It is important to discuss any liver conditions with your healthcare provider before starting treatment.
- As with all medications, avoid using Qulipta during pregnancy unless advised by your healthcare provider. The safety of atogepant in pregnant women has not been established, and it should only be used if the potential benefit justifies the potential risk to the fetus.
- Consult with your healthcare provider before using Qulipta while breastfeeding, as the drug’s effects on infants have not been well studied.
